Acute lung injury occurs when our lung’s immune system response becomes hyperactivated and causes inflammation to continue unchecked. In fact, many deaths from COVID-19 were from acute lung injury.
Researchers at the University of Florida College of Medicine have discovered how common age-related changes in the blood system can make certain colon cancers grow faster.
A new study by Indiana University School of Medicine researchers uses more genetically diverse mouse models to study the accumulation and spread of abnormal tau protein deposits in the brain.
Enzyme mutations have been of great interest to scientists who study cancer. Scientists in the Liu and Tan labs at UNC’s Lineberger Comprehensive Cancer Center have been studying mutations of enzyme recognition motifs in substrates, which may more faithfully reflect enzyme function with the potential to find new targets or directions for cancer treatment.
Scientists have spent years trying to develop an effective HIV vaccine, but none have proven successful. Based on findings from a recently published study, a Johns Hopkins Medicine-led research team may have put science one step closer to that goal.
A UC Davis study is the first to report on a material transfer mechanism from cells, known as oligodendrocytes, to neurons in the brain of a mouse model. This discovery opens new possibilities for understanding brain maturation and finding treatments for many neurological conditions.
Fresh insights into how our bodies interact with the microbes living in our guts suggest that a two-drug combination may offer a new way to treat inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.
A team of scientists from the Renaissance School of Medicine (RSOM) at Stony Brook University have identified a distinct role of retinoic acid, a metabolite of vitamin A, during the immune response of the gut.
The cellular glitches underlying a rare genetic disorder called activated PI3K Delta syndrome 2 (APDS2) have been identified by researchers at the Garvan Institute of Medical Research.
视网膜色素变性症是人类失明的主要原因之一。中国的研究人员成功地恢复了患有视网膜色素变性症的小鼠的视力。该研究将于[三月十七日]发表在《实验医学杂志》上。该研究使用一种新型的、高度通用的CRISPR基因组编辑技术，有潜力纠正各种导致疾病的遗传突变。
Researchers in China have successfully restored the vision of mice with retinitis pigmentosa, one of the major causes of blindness in humans. The study, to be published March 17 in the Journal of Experimental Medicine, uses a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing genetic mutations.
Read how researchers discovered genetic markers that hinder pancreatic cancer treatment and mutations that increase sarcoma risk. Then learn how artificial intelligence is helping predict prostate cancer outcomes and see how a new clinical trial looks at less-invasive breast cancer treatments. Finally, find out how a new grant could help veterans get the cancer care they need.
An SOS signals a call for immediate action during an emergency to request a need for protection.
Irvine, Calif., Jan. 30, 2023 — Combating Alzheimer’s and other neurodegenerative diseases by inserting healthy new immune cells into the brain has taken a leap toward reality. Neuroscientists at the University of California, Irvine and the University of Pennsylvania have found a way to safely thwart the brain’s resistance to them, vaulting a key hurdle in the quest.
Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York have discovered that common cancer treatments, such as radiotherapy or anthracycline drugs, cause long-term damage to heart tissue by activating a key inflammatory signaling pathway. The study, published December 19 in the Journal of Experimental Medicine (JEM), suggests that inhibiting this pathway could reduce the chances of cancer survivors suffering heart disease later in life.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising targeted therapy combination for patients with relapsed/refractory acute myeloid leukemia (AML), a link between the gut microbiome and therapy-related neutropenic fever, a novel therapeutic target for immunotherapy-related colitis, a telementoring model for training providers on cervical cancer prevention in limited-resource areas, a new understanding of the prognostic value of RUNX1 mutations in AML, and insights into the effects of opioid use on the pain sensitivity pathway.
Sex differences in the aging brain may offer an enticing clue for researching more effective neuroprotective treatments, according to a new treatment development strategy laid out by UCLA researchers.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
Researchers in Germany have discovered that age-dependent impairments in antiviral interferon proteins underlie the increased susceptibility of older patients to severe COVID-19. The study, published today in the Journal of Experimental Medicine (JEM), shows that aged mice infected with SARS-CoV-2 are protected from severe disease by treatment with one of these interferons, IFN-γ.
Mount Sinai study also shows catching up on sleep doesn’t reverse possible negative effects on cellular level
Researchers in China have discovered that inhibiting a protein called the GABAA receptor can protect intestinal stem cells from the toxic effects of chemotherapy and radiotherapy. The study, published September 20 in the Journal of Experimental Medicine (JEM), suggests that the FDA-approved anti-sedative flumazenil, which targets GABAA receptors, could alleviate some of the common gastrointestinal side effects, such as diarrhea and vomiting, induced by many cancer treatments.
Researchers at the University of Illinois Chicago have discovered that increasing the production of new neurons in mice with Alzheimer’s disease (AD) rescues the animals’ memory defects. The study, to be published August 19 in the Journal of Experimental Medicine (JEM), shows that new neurons can incorporate into the neural circuits that store memories and restore their normal function, suggesting that boosting neuron production could be a viable strategy to treat AD patients.
Researchers at Stanford University have developed “decoy receptor” molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to be published July 26 in the Journal of Experimental Medicine (JEM), were also found to be nontoxic in monkeys, suggesting they could be used to treat humans with either of these deadly diseases, which are two of the most common blood cancers around the world.
Triptans, a commonly prescribed class of migraine drugs, may also be useful in treating obesity, a new study by scientists at UT Southwestern suggests. In studies on obese mice, a daily dose of a triptan led animals to eat less food and lose weight over the course of a month, the team reported in the Journal of Experimental Medicine.
Although the different SARS-CoV-2 variants currently in circulation are undoubtedly less severe in vaccinated individuals in the general population, immunocompromised people are at greater risk of developing severe forms of COVID-19.
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection.
To treat and prevent these diseases, researchers need to understand why a lack of oxygen would affect the immune system.
A research group led by Kazunobu Sawamoto, a professor at Nagoya City University and National Institute for Physiological Sciences, and Chihiro Kurematsu, a student at Nagoya City University School of Medicine, has elucidated the mechanism that controls synaptic pruning of new neurons in the adult brain. These findings are expected to be useful in the study of neurological diseases with abnormalities in microglia and synapses, such as autism spectrum disorders (ASDs).
Researchers at the University of California, San Francisco (UCSF), have discovered that cells carrying the most common mutation found in human cancer accumulate large amounts of ferrous iron and that this “ferroaddiction” can be exploited to specifically deliver powerful anticancer drugs without harming normal, healthy cells. The therapeutic strategy, described in a study to be published March 9 in the Journal of Experimental Medicine (JEM), could be used to treat a wide variety of cancers driven by mutations in the KRAS gene.
Studying mice, researchers at Washington University School of Medicine in St. Louis have discovered that roseolovirus can trigger autoimmunity in a previously unknown way: by disrupting the process by which immune cells learn to avoid targeting their own body's cells and tissues.
PIK3CA-related overgrowth spectrum (PROS) is a group of rare, incurable disorders caused by mutations in the PIK3CA gene that result in the malformation and overgrowth of various parts of the body. A new report to be published January 26 in the Journal of Experimental Medicine (JEM) describes the successful treatment of two young infants with PROS using the breast cancer drug alpelisib.
Perturbing the gut microbiome with antibiotics during early life leads to a reduction in amyloid plaques in male mice in adulthood — and microglia are a critical component of the effect.
USC study published in the Journal of Experimental Medicine shows that experimental drug protects against injury caused by tiny blood clots in the brain’s white matter, which can accumulate over time and lead to cognitive decline
A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate. The study, published November 23 in the Journal of Experimental Medicine (JEM), could lead to new treatments that prevent the recurrence or spread of various cancer types, including breast cancer and head and neck squamous cell carcinoma (HNSCC).
Researchers at Yale School of Medicine have discovered that an RNA molecule that stimulates the body’s early antiviral defense system can protect mice from a range of emerging SARS-CoV-2 variants. The study, published today in the Journal of Experimental Medicine (JEM), could lead to new treatments for COVID-19 in immunocompromised patients, as well as providing an inexpensive therapeutic option for developing countries that currently lack access to vaccines.
Researchers in Japan have developed a vaccination strategy in mice that promotes the production of antibodies that can neutralize not only SARS-CoV-2 but a broad range of other coronaviruses as well. If successfully translated to humans, the approach, to be published October 8 in the Journal of Experimental Medicine, could lead to the development of a next-generation vaccine capable of preventing future coronavirus pandemics.
Researchers at Cornell have developed a way to analyze how individual immune cells react to the bacteria that cause tuberculosis. It could pave the way for new vaccine strategies and provide insights into fighting other infectious diseases.
Researchers at Weill Cornell Medicine and NewYork-Presbyterian in New York have discovered that injecting mice with pulmonary endothelial cells—the cells that line the walls of blood vessels in the lung—can reverse the symptoms of emphysema. The study, which will be published July 21 in the Journal of Experimental Medicine (JEM), may lead to new treatments for chronic obstructive pulmonary disease (COPD), an inflammatory lung disease associated with smoking that is thought to be the third leading cause of death worldwide.
Exposure to the rhinovirus, the most frequent cause of the common cold, can protect against infection by the virus which causes COVID-19, Yale researchers have found.
St. Jude immunologists are researching how effector and killer T cells can be controlled to destroy cancer cells that resist treatment.
Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors—tumors that often spread and are difficult to treat.
DALLAS – May 12, 2021 – Scientists with UT Southwestern’s Peter O’Donnell Jr. Brain Institute have identified the molecular mechanism that can cause weight gain for those using a common antipsychotic medication. The findings, published in the Journal of Experimental Medicine, suggest new ways to counteract the weight gain, including a drug recently approved to treat genetic obesity, according to the study, which involved collaborations with scientists at UT Dallas and the Korea Advanced Institute of Science and Technology.
Using a mouse model, researchers discover pivotal role of cholesterol in chronic pain often caused by chemotherapy, and propose novel therapy.
Using whole exome sequencing, CHOP researchers discovered the genetic mutation responsible for a condition that prevents patients from making B cells and antibodies to fight infections. The study describing the condition, which CHOP researchers named PU.1 Mutated agammaglobulinemia (PU.MA), was published today in the Journal of Experimental Medicine.
New basic science research shows what happens to the development of abdominal aortic aneurysms when you inhibit JMJD3 through both genetics and pharmacology.
A novel mechanism has been identified that might explain why a rare mutation is associated with familial Alzheimer’s disease in a new study by investigators at the University of Chicago.
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the Journal of Experimental Medicine (JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
